Clinical and histological study of follicular helper T-cell lymphomas with indolent evolution
We describe here the features of a cohort of TFHL patients who experienced prolonged survival despite the absence of specific treatment or the initiation of steroid-based therapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 11, 2023 Category: Cancer & Oncology Authors: Ondine Mess éant, Fanny Drieux, Nouhoum Sako, Virginie Fataccioli, Vincent Camus, Cyrielle Robe, Roch Houot, Patrick Tas, Francisco Llamas-Gutierrez, Claire Lamaison, Julie Abraham, Manuela Delage-Corre, Soraya Benguerfi, Jean-Baptiste Bossard, Philippe Tags: Original Research Source Type: research
TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading
This study aims to determine if TTF-1 ’s prognostic impact is solely based on histomorphological differentiation (tumor grading) or if it independently relates to a biologically more aggressive phenotype. We analyzed a large bi-centric LUAD cohort to accurately assess TTF-1’s prognostic value in relation to tumor grade. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 10, 2023 Category: Cancer & Oncology Authors: Simon Schallenberg, Gabriel Dernbach, Mihnea P. Dragomir, Georg Schlachtenberger, Kyrill Boschung, Corinna Friedrich, Kai Standvoss, Lukas Ruff, Philipp Anders, Christian Grohe ́, Winfried Randerath, Sabine Merkelbach-Bruse, Alexander Quaas, Matthias Hel Tags: Original Research Source Type: research
Midgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature
When compared to other types of cancer, the prevalence of midgut neuroendocrine tumors (NET) has disproportionally increased over the past decades. To date, there has been very little progress in discovering (epi)genetic drivers and treatment options for these tumors. Recent microbiome research has revealed that enteroendocrine cells communicate with the intestinal microbiome and has provided novel treatment targets for various other cancer types. Hence, our aim was to analyze the role of the gut microbiome in midgut NET patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 9, 2023 Category: Cancer & Oncology Authors: M.C.F. Mulders, A.S. Audhoe, P.M. Van Koetsveld, R.A. Feelders, L.J. Hofland, W.W. de Herder, R. Kraaij, J. Hofland Tags: Original Research Source Type: research
Clinical Impact of Proton Pump Inhibitors and Other Co-medications on Advanced Melanoma Patients Treated With BRAF/MEK inhibitors.
While several studies reported the influence of co-medications on immune checkpoint therapy and chemotherapy, it remains poorly studied with targeted therapy. Targeted therapies inhibiting BRAF and MEK had significantly improved management of advanced melanoma with BRAFV600 mutation over the last decade, we aimed to investigate the possible influence of co-mediations on the efficacy and toxicity of these targeted therapies (TT). (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 9, 2023 Category: Cancer & Oncology Authors: Elo ïse Ramel, Sorilla Prey, Caroline Dutriaux, Emilie Gerard, Anne Pham-Ledard, Marie Beylot-Barry, Marie Kostine Tags: Current Perspective Source Type: research
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial
To determine whether the combination of nab-paclitaxel with gemcitabine has activity in patients with pretreated soft tissue sarcoma (STS). (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 8, 2023 Category: Cancer & Oncology Authors: A. Digklia, A. Koll ár, D. Dietrich, M.N. Kronig, C. Britschgi, T. Rordorf, M. Joerger, F. Krasniqi, Y. Metaxas, I. Colombo, K. Ribi, C. Rothermundt Tags: Original Research Source Type: research
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
Treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) treatment failure are limited. An exploratory analysis of 26 patients in the IMpower150 study indicated that treatment with atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) was effective in patients with EGFR-mutated NSCLC. This phase II study was conducted to assess the efficacy of ABCP in EGFR-mutated NSCLC patients after TKI treatment. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 2, 2023 Category: Cancer & Oncology Authors: Satoshi Watanabe, Naoki Furuya, Atsushi Nakamura, Jun Shiihara, Ichiro Nakachi, Hisashi Tanaka, Mika Nakao, Koichi Minato, Masahiro Seike, Shinichi Sasaki, Akira Kisohara, Susumu Takeuchi, Ryoichi Honda, Kei Takamura, Hiroshi Kagamu, Kenichi Yoshimura, Ku Tags: Original Research Source Type: research
Unlocking the Potential of AI-Assisted Pathology for Molecular Alteration Screening
In the past few decades, notable advancements in molecular techniques have been witnessed, spanning from capillary-based sequencing technologies to the advent of next-generation sequencing (NGS), a modern method that enables massive parallel sequencing [1,2]. While NGS has increased access to targeted therapies and likely improves patient outcomes in metastatic cancer cases [3], its adoption remains limited. For instance, only 22% of patients with advanced non-small cell lung cancer (NSCLC) in the US had access to NGS according to a recent editorial by Schilsky et al [4]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 1, 2023 Category: Cancer & Oncology Authors: Mihaela Aldea, Maria Rosa Ghigna, Magali Lacroix-Triki, Fabrice Andre Tags: Editorial Source Type: research
Adjuvant chemotherapy in patients with clinically node-negative but pathologically node-positive rectal cancer in the Netherlands: a retrospective analysis.
Accurate clinical staging of rectal cancer is hampered by suboptimal sensitivity of MRI in the detection of regional lymph node metastases. Consequently, some patients may be understaged and have been withheld neoadjuvant (chemo)radiotherapy in retrospect. Although Dutch guidelines do not advocate adjuvant chemotherapy (ACT) in rectal cancer, some of these clinically understaged patients receive ACT according to local policy. We aim to assess the benefit of ACT in these patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 1, 2023 Category: Cancer & Oncology Authors: Johannes J.M. Kwakman, Marinde J.G. Bond, Ramzi M. Demichelis, Miriam Koopman, Roel Hompes, Marloes A.G. Elferink, Cornelis J.A. Punt Tags: Original Research Source Type: research
Characteristics and post-metastasis survival of recurrent metastatic breast cancer over time – An Australian population-based record linkage study, 2001-2016.
To assess population-level characteristics and post-metastasis survival of people with recurrent metastatic breast cancer (rMBC) during a period when new publicly-subsidised adjuvant and metastatic systemic therapies became available. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 1, 2023 Category: Cancer & Oncology Authors: Sarah J Lord, Belinda E Kiely, Dianne L O'Connell, Benjamin Daniels, Jane Beith, Andrea L. Smith, Sallie-Anne Pearson, Kim-Lin Chiew, Max K Bulsara, Nehmat Houssami Tags: Original Research Source Type: research
Editorial Board
(Source: European Journal of Cancer)
Source: European Journal of Cancer - November 24, 2023 Category: Cancer & Oncology Source Type: research
Letter re: Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial
To the Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 24, 2023 Category: Cancer & Oncology Authors: Erkan Topkan, Efsun Somay, Ugur Selek, Berrin Pehlivan Tags: Letter to the Editor Source Type: research
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)
BRAF+MEK inhibitors extend life expectancy of patients with BRAF V600 mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this limitation. INTERIM was a phase 2 trial evaluating an intermittent dosing regimen. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 23, 2023 Category: Cancer & Oncology Authors: Alimu Dayimu, Avinash Gupta, Rubeta N Matin, Jenny Nobes, Ruth Board, Miranda Payne, Ankit Rao, Alberto Fusi, Sarah Danson, Bryony Eccles, Judith Carser, Ciara O ’Hanlon Brown, Neil Steven, Madhumita Bhattacharyya, Ewan Brown, Michael Gonzalez, Martin H Tags: Original Research Source Type: research
Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years
We report on the nationwide exhaustive series of 330 patients with SEF or LGFMS in NETSARC+ since 2010. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 23, 2023 Category: Cancer & Oncology Authors: JY Blay, C. Tlemsani, M Toulmonde, A. Italiano, M. Rios, E. Bompas, T. Valentin, F. Duffaud, LR Le Nail, S. Watson, N Firmin, P Dubray-Longeras, M Ropars, C. Perrin, A Hervieu, C Lebbe, E Saada-Bouzid, P. Soibinet, F. Fiorenza, F. Bertucci, P. Boudou, G V Tags: Original Research Source Type: research
First-in-Human Study of Naporafenib (LXH254) With or Without Spartalizumab in Adult Patients With Advanced Solid Tumors Harboring MAPK Signaling Pathway Alterations
We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway alterations. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 20, 2023 Category: Cancer & Oncology Authors: Filip Janku, Tae Min Kim, Gopakumar Iyer, Anna Spreafico, Elena Elez, Maja de Jonge, Noboru Yamamoto, Anthonie J. van der Wekken, Paolo Antonio Ascierto, Michela Maur, Frederik Marm é, Jean-Jacques Kiladjian, Sumit Basu, Fabienne Baffert, Amparo Buigues, Tags: Original Research Source Type: research
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): a randomized, open-label, multicenter, phase II trial
Metastatic breast cancer refractory to anthracycline and taxanes often shows rapid progression. The development of effective and tolerable combination regimens for these patients is needed. This phase II trial investigated the efficacy of pemetrexed plus vinorelbine in patients with metastatic breast cancer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 20, 2023 Category: Cancer & Oncology Authors: Dae-Won Lee, Kyung Hae Jung, Kyung-Hun Lee, Yeon Hee Park, Keun Seok Lee, Joohyuk Sohn, Hee Kyung Ahn, Jae Ho Jeong, Su-Jin Koh, Jee Hyun Kim, Han Jo Kim, Kyoung Eun Lee, Hee-Jun Kim, Yae-Won Yang, Kyong Hwa Park, Jieun Lee, Hye Sung Won, Tae-Yong Kim, Se Tags: Original Research Source Type: research
